XOMA (NASDAQ:XOMA) Stock Rating Lowered by StockNews.com

XOMA (NASDAQ:XOMA - Get Free Report) was downgraded by research analysts at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Monday.

Separately, HC Wainwright dropped their price objective on shares of XOMA from $123.00 to $104.00 and set a "buy" rating for the company in a research report on Monday.

XOMA Trading Down 2.1 %

XOMA traded down $0.56 during midday trading on Monday, hitting $25.55. The company's stock had a trading volume of 10,457 shares, compared to its average volume of 54,606. The firm has a market cap of $300.98 million, a P/E ratio of -7.34 and a beta of 0.90. XOMA has a 52-week low of $19.50 and a 52-week high of $35.00. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm has a 50-day moving average price of $27.28 and a two-hundred day moving average price of $28.03.

XOMA (NASDAQ:XOMA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.44) by $0.05. The company had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.66 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. On average, research analysts anticipate that XOMA will post -1.41 earnings per share for the current year.

Insider Activity

In other XOMA news, CEO Owen Hughes sold 21,881 shares of the stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the transaction, the chief executive officer now owns 34,979 shares of the company's stock, valued at $1,047,621.05. This trade represents a 38.48 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The disclosure for this sale can be found here. Insiders own 7.20% of the company's stock.

Hedge Funds Weigh In On XOMA

Large investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. increased its stake in shares of XOMA by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company's stock valued at $607,000 after purchasing an additional 1,276 shares during the period. Los Angeles Capital Management LLC bought a new position in shares of XOMA in the fourth quarter valued at approximately $206,000. New York State Common Retirement Fund boosted its stake in XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 800 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of XOMA by 18.1% in the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company's stock valued at $291,000 after buying an additional 1,699 shares during the period. Finally, Barclays PLC boosted its stake in XOMA by 300.7% during the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company's stock valued at $298,000 after buying an additional 8,447 shares in the last quarter. Institutional investors own 95.92% of the company's stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.